Literature DB >> 32768570

Role of Nrf2 dysfunction in the pathogenesis of diabetic nephropathy: Therapeutic prospect of epigallocatechin-3-gallate.

Thangarajeswari Mohan1, Kishore Kumar S Narasimhan2, Divya Bhavani Ravi1, Prema Velusamy1, Navvi Chandrasekar3, Lakshmi Narasimhan Chakrapani1, Ashokkumar Srinivasan1, Porkodi Karthikeyan1, Pugazhendhi Kannan1, Bhavani Tamilarasan1, Thanka Johnson4, Parkavi Kalaiselvan5, Kalaiselvi Periandavan6.   

Abstract

Diabetic nephropathy (DN), a progressive kidney disease afflicts more than 20 and up to 40% of the diabetic population and it is characterized by persistent microalbuminuria declined glomerular filtration rate. The interesting feature associated with DN is that, even though the progression of the disease correlates with oxidative stress, Nrf2, the master regulator of antioxidant defense system involved in counteracting oxidative stress is also upregulated in the diabetic kidneys of both human as well as experimental animals in early stages of DN. Despite the increased expression, the ability of this protein to get translocated into the nucleus is diminished signifying the functional impairment of Nrf2, implying redox imbalance. Hence, it is understood that agents that boost the translocation of Nrf2 might be beneficial rather than those that quantitatively overexpress Nrf2 in treating DN. The deleterious effects of synthetic Nrf2 activators have instigated the researchers to search for phytochemicals that have ambient Nrf2 boosting ability with no side effects, one such phytochemical is Epigallocatechin-3-gallate (EGCG) and it has shown beneficial effects by preventing the progression of DN via influencing Nrf2/ARE pathway, however, the modus operandi is unclear, despite speculations. This study was designed to find out whether supplementation of Nrf2 booster like EGCG at the crucial time of Nrf2 dysfunction can mitigate the progression of DN. Based on the findings of the present study, it might be concluded that the beneficial effect of EGCG in mitigating DN is mediated mainly through its ability to activate the Nrf2/ARE signaling pathway at multiple stages i.e., by downregulating Keap1 and boosting the nuclear Nrf2 level by disrupting Nrf2-Keap1 interaction. These results emphasize that supplementation of EGCG might be more beneficial at an early stage of DN, where dysfunctional Nrf2 accumulation occurs, which should be further validated.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Diabetic nephropathy; Epigallocatechin-3-gallate; Nrf2 activator; Nrf2 dysfunction; Oxidative stress

Mesh:

Substances:

Year:  2020        PMID: 32768570     DOI: 10.1016/j.freeradbiomed.2020.07.037

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  6 in total

1.  Protective Effect of Liposomal Epigallocatechin-Gallate in Experimental Gentamicin-Induced Hepatotoxicity.

Authors:  Adriana Elena Bulboacă; Alina Silvia Porfire; Vasile Rus; Cristina Ariadna Nicula; Corneliu Angelo Bulboacă; Sorana D Bolboacă
Journal:  Antioxidants (Basel)       Date:  2022-02-17

Review 2.  Polyphenols and Their Metabolites in Renal Diseases: An Overview.

Authors:  Íris Guerreiro; Cíntia Ferreira-Pêgo; Diogo Carregosa; Cláudia N Santos; Regina Menezes; Ana S Fernandes; João G Costa
Journal:  Foods       Date:  2022-04-06

Review 3.  Nrf2 Activation in Chronic Kidney Disease: Promises and Pitfalls.

Authors:  Ana Karina Aranda-Rivera; Alfredo Cruz-Gregorio; José Pedraza-Chaverri; Alexandra Scholze
Journal:  Antioxidants (Basel)       Date:  2022-06-03

4.  Decreased Urine N6-methyladenosine level is closely associated with the presence of diabetic nephropathy in type 2 diabetes mellitus.

Authors:  Shu-Jun Wan; Qiang Hua; Yu-Jie Xing; Yi Cheng; Si-Min Zhou; Yue Sun; Xin-Ming Yao; Xiang-Jian Meng; Jin-Han Cheng; Han Wu; Qing Zhai; Yan Zhang; Xiang Kong; Kun Lv
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-27       Impact factor: 6.055

Review 5.  A Comprehensive Review on Beneficial Effects of Catechins on Secondary Mitochondrial Diseases.

Authors:  Baoyi Chen; Wenting Zhang; Chuyuan Lin; Lingyun Zhang
Journal:  Int J Mol Sci       Date:  2022-09-30       Impact factor: 6.208

Review 6.  Bioactive Compounds in Oxidative Stress-Mediated Diseases: Targeting the NRF2/ARE Signaling Pathway and Epigenetic Regulation.

Authors:  Muthu Thiruvengadam; Baskar Venkidasamy; Umadevi Subramanian; Ramkumar Samynathan; Mohammad Ali Shariati; Maksim Rebezov; Shabari Girish; Sivakumar Thangavel; Anand Raj Dhanapal; Natalya Fedoseeva; Joohyun Lee; Ill-Min Chung
Journal:  Antioxidants (Basel)       Date:  2021-11-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.